Core Insights - Ardelyx, Inc. presented new clinical data on IBSRELA® (tenapanor) at the 2024 Digestive Disease Week Conference, highlighting its safety and efficacy for treating irritable bowel syndrome with constipation (IBS-C) in adults [1][2] - The data includes a post hoc analysis from the Phase 3 T3MPO-1 and T3MPO-2 studies, showing clinically meaningful responses to tenapanor regardless of prior medication use [2] - Efficacy of tenapanor was found to be comparable or more pronounced in Hispanic patients compared to non-Hispanic patients [3] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [1][12] - The company has two commercial products approved in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [12] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships in Japan and Canada [12] Product Information - IBSRELA (tenapanor) is a first-in-class treatment approved by the FDA for IBS-C in adults, acting as a sodium/hydrogen exchanger 3 (NHE3) inhibitor [1][4] - The mechanism of action involves reducing sodium absorption in the intestines, which helps retain water and improve stool consistency [4] - IBS-C affects an estimated 12 million people in the U.S., leading to impaired quality of life and economic burden [5]

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA® (tenapanor) was presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment that is appr ...

Group 1: Ardelyx (ARDX) - Ardelyx is a biopharmaceutical company with FDA-approved products, leading to significant revenue growth [2][3] - The company's primary product, Ibsrela, generated $28.4 million in net product sales in Q1 2024, driven by an expanding list of healthcare providers [2] - Ardelyx's second product, Xphozah, for chronic kidney disease, brought in $15.2 million in net product sales in the same quarter, with expectations for further growth from international approvals [3] Group 2: Sirius XM (SIRI) - Sirius XM is a satellite radio provider with a subscriber base of nearly 34 million, maintaining profitability for over 10 years [5][6] - Despite a recent dip in stock price, the company generated $2.16 million in revenue and $132 million in free cash flow in Q1 2024 [5] - Sirius XM projects approximately $8.75 billion in revenue for 2024, bolstered by its 360L platform and the Pandora streaming app, which contributes around 25% of Q1 revenue [6] Group 3: VAALCO Energy (EGY) - VAALCO Energy is an independent oil and gas producer with operations in multiple countries, benefiting from increased demand due to geopolitical events [7] - The company reported a net income of $7.7 million in Q1 2024, up from $3.4 million in Q1 2023, despite higher depreciation and operating expenses [7] - VAALCO Energy maintains a dividend yield of 4% and is expected to continue growth as production capacity increases, particularly with the resumption of operations in its Baobab oil field [8]

Core Insights - Ardelyx, Inc. presented positive clinical data for XPHOZAH® (tenapanor) at the NKF 2024 Spring Clinical Meetings, highlighting its potential impact on managing hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis [1][3] Company Overview - Ardelyx is a biopharmaceutical company focused on developing innovative, first-in-class medicines to address significant unmet medical needs [1][14] - The company has two commercial products approved in the U.S., including IBSRELA® and XPHOZAH® [14] Product Information - XPHOZAH is the first and only phosphate absorption inhibitor approved by the FDA for reducing serum phosphorus in adults with CKD on dialysis [2][13] - It is administered as a single tablet taken twice daily and works by blocking phosphate absorption at the primary pathway [2][7] Clinical Data Highlights - A poster presentation indicated that adding tenapanor to sevelamer treatment improved phosphate control, as measured by average daily phosphate area under the curve (AUC) [3][4] - Another analysis showed that tenapanor's efficacy and safety were consistent across different age groups and comorbidities in dialysis patients [4] - A study on patient perception revealed that 80% of patients felt their phosphate management improved with tenapanor, leading to better adherence to therapy [5] Industry Context - Hyperphosphatemia is a prevalent condition among the 550,000 CKD patients on dialysis in the U.S., necessitating effective management strategies [9] - The KDIGO guidelines recommend lowering elevated phosphate levels to the normal range of 2.5-4.5 mg/dL [9]

WALTHAM, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH® (tenapanor) was presented in a series of poster presentations at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, now underway in Long Beach, California. ...

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irrita ...

Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - President & Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Chris Raymond - Piper Sandler Yigal Nochomovitz - Citi Louise Chen - Cantor Fitzgerald Ryan Deschner - Raymond James Dennis Ding - Jefferies R ...

Table of Contents Non-accelerated filer ☐ Smaller reporting company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC. (Exact Name of Registrant as Specified ...

Exhibit 99.1 Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 2, 2024 - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a missio ...

Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines ...